|
1.
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC: World Health Organization Classification of
Tumours. Pathology and Genetics of Tumours of the Lung, Pleura,
Thymus and Heart. IARC Press; Lyon: 2004
|
|
2.
|
Travis WD, Rush W, Flieder DB, Falk R,
Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary
neuroendocrine tumors with clarification of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J Surg
Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Canessa PA, Santini D, Zanelli M and
Capecchi V: Pulmonary tumourlets and microcarcinoids in
bronchiectasis. Monaldi Arch Chest Dis. 52:138–139. 1997.PubMed/NCBI
|
|
4.
|
Watanabe H, Kobayashi H, Honma K, Ohnishi
Y and Iwafuchi M: Diffuse panbronchiolitis with multiple tumorlets.
A quantitative study of the Kultschitzky cells and the clusters.
Acta Pathol Jpn. 35:1221–1231. 1985.PubMed/NCBI
|
|
5.
|
Granberg D, Wilander E, Oberg K and
Skogseid B: Prognostic markers in patients with typical bronchial
carcinoid tumors. J Clin Endocrinol Metab. 85:3425–3430.
2000.PubMed/NCBI
|
|
6.
|
Cooper WA, Thourani VH, Gal AA, Lee RB,
Mansour KA and Miller JI: The surgical spectrum of pulmonary
neuroendocrine neoplasms. Chest. 119:14–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Asamura H, Kameya T, Matsuno Y, Noguchi M,
Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima
K and Nagai K: Neuroendocrine neoplasms of the lung: a prognostic
spectrum. J Clin Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Gustafsson BI, Kidd M, Chan A,
Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine
tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Onuki N, Wistuba II, Travis WD, Virmani
AK, Yashima K, Brambilla E, Hasleton P and Gazdar AF: Genetic
changes in the spectrum of neuroendocrine lung tumors. Cancer.
85:600–607. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Debelenko LV, Brambilla E, Agarwal SK, et
al: Identification of MEN1 gene mutations in sporadic carcinoid
tumors of the lung. Hum Mol Genet. 6:2285–2290. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Marinov M, Ziogas A, Pardo OE, Tan LT,
Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U,
Seckl MJ and Arcaro A: AKT/mTOR pathway activation and BCL-2 family
proteins modulate the sensitivity of human small cell lung cancer
cells to RAD001. Clin Cancer Res. 15:1277–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
|
|
15.
|
Peterson RT, Beal PA, Comb MJ and
Schreiber SL: FKBP12-rapamycin-associated protein (FRAP)
autophosphorylates at serine 2481 under translationally repressive
conditions. J Biol Chem. 275:7416–7423. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Akcakanat A, Sahin A, Shaye AN, Velasco MA
and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary
breast tumors and matched distant metastases. Cancer.
112:2352–2358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Marinov M, Fischer B and Arcaro A:
Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol.
63:172–182. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Pitt SC, Chen H and Kunnimalaiyaan M:
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid
cells. J Am Coll Surg. 209:82–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Zatelli MC, Minoia M, Martini C, Tagliati
F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E,
Cavallesco G, Berdondini L, Rea F and degli Uberti EC: Everolimus
as a new potential antiproliferative agent in aggressive human
bronchial carcinoids. Endocr Relat Cancer. 17:719–729. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Tsurutani J, West KA, Sayyah J, Gills JJ
and Dennis PA: Inhibition of the phosphatidylinositol
3-kinase/Akt/mammalian target of rapamycin pathway but not the
MEK/ERK pathway attenuates laminin-mediated small cell lung cancer
cellular survival and resistance to imatinib mesylate or
chemotherapy. Cancer Res. 65:8423–8432. 2005. View Article : Google Scholar
|
|
21.
|
Mamane Y, Petroulakis E, LeBacquer O and
Sonenberg N: mTOR, translation initiation and cancer. Oncogene.
25:6416–6422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sobin LH, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; NJ: 2009
|
|
23.
|
Vignot S, Faivre S, Aguirre D and Raymond
E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann
Oncol. 16:525–537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Krystal GW, Sulanke G and Litz J:
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks
growth, promotes apoptosis, and enhances sensitivity of small cell
lung cancer cells to chemotherapy. Mol Cancer Ther. 1:913–922.
2002.PubMed/NCBI
|
|
25.
|
Pandya KJ, Dahlberg S, Hidalgo M, Cohen
RB, Lee MW, Schiller JH and Johnson DH; Eastern Cooperative
Oncology Group (E1500): A randomized, phase II trial of two dose
levels of temsirolimus (CCI-779) in patients with extensive-stage
small-cell lung cancer who have responding or stable disease after
induction chemotherapy: a trial of the Eastern Cooperative Oncology
Group (E1500). J Thorac Oncol. 2:1036–1041. 2007. View Article : Google Scholar
|
|
26.
|
Massion PP, Taflan PM, Shyr Y, Rahman SM,
Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ and
Gonzalez AL: Early involvement of the phosphatidylinositol
3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit
Care Med. 170:1088–1094. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shah T, Hochhauser D, Frow R, Quaglia A,
Dhillon AP and Caplin ME: Epidermal growth factor receptor
expression and activation in neuroendocrine tumours. J
Neuroendocrinol. 18:355–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Dobashi Y, Suzuki S, Matsubara H, Kimura
M, Endo S and Ooi A: Critical and diverse involvement of
Akt/mammalian target of rapamycin signaling in human lung
carcinomas. Cancer. 115:107–118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Righi L, Volante M, Rapa I, Tavaglione V,
Inzani F, Pelosi G and Papotti M: Mammalian target of rapamycin
(mTOR) signaling activation patterns in neuroendocrine tumors of
the lung. Endocr Relat Cancer. 17:977–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chadha KS, Khoury T, Yu J, Black JD, Gibbs
JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt
and Erk expression and survival after surgery in pancreatic
carcinoma. Ann Surg Oncol. 13:933–939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Gingras AC, Raught B and Sonenberg N:
Regulation of translation initiation by FRAP/mTOR. Genes Dev.
15:807–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Montagne J, Stewart MJ, Stocker H, Hafen
E, Kozma SC and Thomas G: Drosophila S6 kinase: a regulator of cell
size. Science. 285:2126–2129. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Gugger M, Burckhardt E, Kappeler A,
Hirsiger H, Laissue JA and Mazzucchelli L: Quantitative expansion
of structural genomic alterations in the spectrum of neuroendocrine
lung carcinomas. J Pathol. 196:408–415. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Pinchot SN, Holen K, Sippel RS and Chen H:
Carcinoid tumors. Oncologist. 13:1255–1269. 2008. View Article : Google Scholar : PubMed/NCBI
|
